Biogen (BIIB) & Samsung Bioepis Report Settlement with AbbVie (ABBV) for Commercialization of IMRALDI (Adalimumab Biosimilar) in Europe
Tweet Send to a Friend
Biogen Inc. (NASDAQ: BIIB) and its partner Samsung Bioepis announced today an agreement with AbbVie (NYSE: ABBV) for the commercialization ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
